SLC41A1的过度表达与HCC的免疫细胞透相关,并促进其恶性进展
Gang Chen1,2, Zhipeng Du3, Caijun Rao1
1Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
International journal of medical sciences
|December 4, 2024
概括
溶性载体家族41成员1 (SLC41A1) 在肝细胞癌 (HCC) 中被上调,作为瘤促进剂. 准SLC41A1为新的HCC诊断标记物和治疗提供了潜力.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 溶解物载体41 (SLC41) 载体,包括SLC41A3,与癌症进展有关.
- 在肝细胞癌 (HCC) 中SLC41A1的作用尚未明确定义.
- 了解SLC41A1在HCC中的功能对于开发向疗法至关重要.
研究的目的:
- 研究SLC41A1在HCC中的表达水平和功能机制.
- 评估SLC41A1作为HCC的潜在诊断和预后生物标志物.
- 探索与HCC中SLC41A1相关的分子通路和免疫细胞相互作用.
主要方法:
- 生物信息分析包括基因本体学 (GO),基因和基因组的京都百科全书 (KEGG) 和基因组丰富分析 (GSEA).
- 使用MethSurv和蛋白质与蛋白质相互作用 (PPI) 网络分析DNA甲基化.
- 免疫组织化学染色,细胞实验 (敲击和过度表达) 和单样GSEA (ssGSEA).
主要成果:
- 发现SLC41A1在HCC组织上升调节,并与临床病理特征相关.
- SLC41A1的DNA甲基化与HCC患者的整体存活率有关.
- SLC41A1的过度表达促进了HCC细胞的增殖,迁移和入侵,并与促进瘤通路和免疫细胞透有关.
结论:
- SLC41A1作为HCC的独立诊断和预后标志物.
- 通过各种分子途径和免疫调节,SLC41A1在HCC进展中发挥着重要作用.
- SLC41A1代表了HCC治疗的一个有前途的治疗点.
更多相关视频
相关概念视频
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Induced Pluripotent Stem Cells
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Somatic cells are...


